MA54865A - Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration - Google Patents
Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administrationInfo
- Publication number
- MA54865A MA54865A MA054865A MA54865A MA54865A MA 54865 A MA54865 A MA 54865A MA 054865 A MA054865 A MA 054865A MA 54865 A MA54865 A MA 54865A MA 54865 A MA54865 A MA 54865A
- Authority
- MA
- Morocco
- Prior art keywords
- furosemide
- administration
- methods
- pharmaceutical formulations
- concentrated liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799215P | 2019-01-31 | 2019-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54865A true MA54865A (fr) | 2022-05-04 |
Family
ID=69740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054865A MA54865A (fr) | 2019-01-31 | 2020-01-30 | Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration |
Country Status (15)
| Country | Link |
|---|---|
| US (10) | US11998555B2 (https=) |
| EP (1) | EP3917495A1 (https=) |
| JP (3) | JP7465881B2 (https=) |
| KR (2) | KR102923666B1 (https=) |
| CN (2) | CN118319852A (https=) |
| AU (2) | AU2020214314B2 (https=) |
| BR (1) | BR112021014637A2 (https=) |
| CA (1) | CA3128033A1 (https=) |
| EA (1) | EA202192129A1 (https=) |
| IL (2) | IL285073B2 (https=) |
| MA (1) | MA54865A (https=) |
| MX (2) | MX2021009084A (https=) |
| PH (1) | PH12021551811A1 (https=) |
| SG (1) | SG11202108280RA (https=) |
| WO (1) | WO2020160210A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2981258T (pt) * | 2013-04-05 | 2020-10-19 | Scpharmaceuticals Inc | Formulações farmacêuticas para administração subcutânea de furosemida |
| PH12021551811A1 (en) | 2019-01-31 | 2022-03-21 | Scpharmaceuticals Inc | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| JP2024512650A (ja) * | 2021-04-02 | 2024-03-19 | エスシーファーマシューティカルズ インコーポレイテッド | フロセミドの皮下注入 |
| EP4648761A1 (en) * | 2023-01-09 | 2025-11-19 | scPharmaceuticals Inc. | Methods of treatment using loop diuretics |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2134671A1 (de) | 1971-07-08 | 1973-01-25 | Josef Dipl Chem Dr Rer N Klosa | Pharmazeutische praeparate |
| US4663348A (en) | 1985-07-02 | 1987-05-05 | Warner-Lambert Co. | Furosemide salts and pharmaceutical preparations thereof |
| US4698361A (en) | 1986-05-28 | 1987-10-06 | Schiena Michele G Di | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same |
| DE3623620A1 (de) | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| US4853439A (en) | 1987-10-09 | 1989-08-01 | Gaf Corporation | Water-soluble complexes of water-insoluble organic compounds |
| EP0416232B1 (en) * | 1989-08-21 | 1995-08-16 | American Cyanamid Company | Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method |
| WO1992021769A1 (en) | 1991-05-30 | 1992-12-10 | Abbott Laboratories | Reagents containing a nonspecific binding blocker in ion-capture binding assays |
| US5633240A (en) | 1994-09-01 | 1997-05-27 | Academic Pharmaceuticals | Parenteral solutions containing metolazone |
| IT1283608B1 (it) * | 1996-04-17 | 1998-04-22 | Ricerche Di Schiena Snc Di Dr | Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva. |
| CN1068778C (zh) | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| ATE409280T1 (de) | 2005-12-28 | 2008-10-15 | Sensile Pat Ag | Mikropumpe |
| MX2009000385A (es) | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
| EP2022518A1 (en) | 2007-08-07 | 2009-02-11 | Sensile Pat AG | Modular drug delivery device for administering discrete doses of a medicament |
| US7923447B2 (en) | 2008-03-17 | 2011-04-12 | Academic Pharmaceuticals Incorporated | Parenteral solutions containing metolazone |
| CA2724540C (en) | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
| EP2334302B1 (en) | 2008-09-09 | 2018-03-21 | Cima Labs Inc | DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE |
| US20110060280A1 (en) | 2009-09-04 | 2011-03-10 | Sean Caffey | Adhesive skin patch with pump for subcutaneous drug delivery |
| AU2012325801B2 (en) | 2011-10-19 | 2016-05-12 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
| CN103371967A (zh) * | 2012-04-17 | 2013-10-30 | 上海禾丰制药有限公司 | 呋塞米注射液及其制剂工艺 |
| EP3682902A1 (en) * | 2012-05-18 | 2020-07-22 | Luoda Pharma Limited | Liquid formulation |
| PT2981258T (pt) * | 2013-04-05 | 2020-10-19 | Scpharmaceuticals Inc | Formulações farmacêuticas para administração subcutânea de furosemida |
| ES3041602T3 (en) | 2018-12-10 | 2025-11-13 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| US12397005B2 (en) | 2019-01-04 | 2025-08-26 | Sq Innovation Ag | Pharmaceutical compositions of torsemide and uses thereof |
| US11246851B2 (en) | 2019-01-04 | 2022-02-15 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| PH12021551811A1 (en) | 2019-01-31 | 2022-03-21 | Scpharmaceuticals Inc | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
-
2020
- 2020-01-30 PH PH1/2021/551811A patent/PH12021551811A1/en unknown
- 2020-01-30 AU AU2020214314A patent/AU2020214314B2/en active Active
- 2020-01-30 WO PCT/US2020/015799 patent/WO2020160210A1/en not_active Ceased
- 2020-01-30 MX MX2021009084A patent/MX2021009084A/es unknown
- 2020-01-30 IL IL285073A patent/IL285073B2/en unknown
- 2020-01-30 KR KR1020217027628A patent/KR102923666B1/ko active Active
- 2020-01-30 BR BR112021014637-7A patent/BR112021014637A2/pt unknown
- 2020-01-30 EP EP20708883.2A patent/EP3917495A1/en active Pending
- 2020-01-30 CN CN202410504521.4A patent/CN118319852A/zh active Pending
- 2020-01-30 KR KR1020267003410A patent/KR20260036554A/ko active Pending
- 2020-01-30 JP JP2021542438A patent/JP7465881B2/ja active Active
- 2020-01-30 SG SG11202108280RA patent/SG11202108280RA/en unknown
- 2020-01-30 CN CN202080019588.9A patent/CN113747881B/zh active Active
- 2020-01-30 CA CA3128033A patent/CA3128033A1/en active Pending
- 2020-01-30 EA EA202192129A patent/EA202192129A1/ru unknown
- 2020-01-30 US US17/426,765 patent/US11998555B2/en active Active
- 2020-01-30 MA MA054865A patent/MA54865A/fr unknown
-
2021
- 2021-07-28 MX MX2023012741A patent/MX2023012741A/es unknown
-
2022
- 2022-02-18 US US17/675,043 patent/US11497755B2/en active Active
- 2022-08-02 US US17/879,041 patent/US11571434B2/en active Active
- 2022-08-05 US US17/817,731 patent/US11559535B2/en active Active
-
2023
- 2023-01-05 US US18/150,590 patent/US12048709B2/en active Active
-
2024
- 2024-04-01 JP JP2024059099A patent/JP7738696B2/ja active Active
- 2024-04-26 US US18/647,335 patent/US12491193B2/en active Active
- 2024-05-17 US US18/667,326 patent/US12491194B2/en active Active
- 2024-05-22 US US18/671,025 patent/US12491195B2/en active Active
- 2024-06-06 US US18/735,889 patent/US12491197B2/en active Active
- 2024-06-06 US US18/735,876 patent/US12491196B2/en active Active
-
2025
- 2025-09-02 JP JP2025145578A patent/JP2025170052A/ja active Pending
- 2025-09-11 IL IL323325A patent/IL323325A/en unknown
- 2025-12-18 AU AU2025283539A patent/AU2025283539A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3813853A4 (en) | DELIVERY COMPOSITIONS AND METHODS OF USE | |
| MA54865A (fr) | Formulations pharmaceutiques liquides concentrées de furosémide et leurs méthodes d'administration | |
| EP3921420A4 (en) | PHARMACEUTICAL DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | |
| EP3357508A4 (en) | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE | |
| EP4277616A4 (en) | Transdermal penetrant formulations for administration of medicaments | |
| EP3840730A4 (en) | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF | |
| EP2343982A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR CHARGING | |
| EP3399963C0 (en) | GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY FOR MAXIMIZING DRUG CONCENTRATION IN THE STRATUM CORNEUM AND SERUM AND METHODS OF USE THEREOF | |
| EP3638205A4 (en) | DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS | |
| EP3908251A4 (en) | MEDICATION DELIVERY COMPOSITIONS AND USES THEREOF | |
| EP3972691A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE | |
| EP3661968A4 (en) | NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY | |
| MA50189A (fr) | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci | |
| EP4297784A4 (en) | COMPOSITIONS AND METHODS OF THERAPEUTIC ADMINISTRATION | |
| EP3946547A4 (en) | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | |
| EP3313379A4 (en) | ORAL PHARMACEUTICAL FORM FOR THE DISTRIBUTION OF A PEPTIDE AND / OR PROTEIN | |
| MA55726A (fr) | Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation | |
| EP3362096A4 (en) | OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| EP3604269A4 (en) | USE OF A COMPOUND OR AN EXTRACT OF TRADITIONAL CHINESE MEDICINE FOR THE MANUFACTURE OF A NUCLEIC ACID DELIVERANT AND RELATED PRODUCTS THEREOF | |
| EP3817774A4 (en) | COMPOSITIONS AND METHODS FOR LOCAL ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER | |
| EP3570835A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF IMMUNINFLAMMABLE DERMAL DISEASES | |
| MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
| EP4171544A4 (en) | PHARMACEUTICAL FORMULATIONS OF GRISEOFULVINE FOR LONG-TERM EYE ADMINISTRATION | |
| EP3860570A4 (en) | FORMULATIONS AND METHODS FOR TRANSDERMAL ADMINISTRATION OF KETONES |